GlassScriptPhysician profile
Jean M Bahu
NPI 1669869954
$3,092.78
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $279 · 2023: $1,243 · 2024: $901 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.30 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $500.78 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $385.10 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $368.93 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $269.21 | 2021-2025 | Tremfya |
| Abbvie INC. | $240.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $238.05 | 2024-2025 | |
| Incyte Corporation | $194.09 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $183.11 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $166.78 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $113.08 | 2021-2024 | |
| Lilly USA, LLC | $86.94 | 2022-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.57 | 2023 | Spevigo, Cyltezo |
| Leo Pharma INC. | $69.69 | 2022-2025 | Anzupgo, Adbry |
| Genentech USA, INC. | $61.18 | 2023-2024 | Xolair |
| Almirall LLC | $37.65 | 2021-2023 | Klisyri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $36.39 | 2023 | Puraply |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
| Ucb, INC. | $16.52 | 2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $13.53 | 2022 | |
| Stemline Therapeutics INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Bahu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.